18F-FDG PET/CT in Restaging and Evaluation of Response to Therapy in Lung Cancer: State of the Art
Open Access
- 30 November 2020
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Radiopharmaceuticals
- Vol. 13 (3) , 228-237
Abstract
Background: Metabolic information provided by 18F-FDG PET/CT are useful for initial staging, therapy planning, response evaluation, and to a lesser extent for the follow-up of non-small cell lung cancer (NSCLC). To date, there are no established clinical guidelines in treatment response and early detection of recurrence. Objective: To provide an overview of 18F-FDG PET/CT in NSCLC and in particular, to discuss its utility in treatment response evaluation and restaging of lung cancer. Methods: A comprehensive search was used based on PubMed results. From all studies published in English those that explored the role of 18F-FDG PET/CT in the treatment response scenario were selected. Results: Several studies have demonstrated that modifications in metabolic activity, expressed by changes in SUV both in the primary tumor as well as in regional lymph nodes, are associated with tumor response and survival. Beside SUV, other metabolic parameters (i.e. MTV, TLG, and percentage changes) are emerging to be helpful for predicting clinical outcomes. Conclusion: 18F-FDG parameters appear to be promising factors for evaluating treatment response and for detecting recurrences, although larger prospective trials are needed to confirm these evidences and to determine optimal cut-off values.Keywords
This publication has 54 references indexed in Scilit:
- 18F-FDG PET Early Response Evaluation of Locally Advanced Non–Small Cell Lung Cancer Treated with Concomitant ChemoradiotherapyJournal of Nuclear Medicine, 2013
- Role of FDG-PET scans in staging, response assessment, and follow-up care for non-small cell lung cancerFrontiers in Oncology, 2013
- Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteriaCancer Imaging, 2013
- 18F-FDG-PET evaluation of pathological tumour response to neoadjuvant therapy in patients with NSCLCNuclear Medicine Communications, 2013
- Tumor Lesion Glycolysis and Tumor Lesion Proliferation for Response Prediction and Prognostic Differentiation in Patients With Advanced Non–Small Cell Lung Cancer Treated With ErlotinibClinical Nuclear Medicine, 2012
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid TumorsJournal of Nuclear Medicine, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC)Lung Cancer, 2008
- Staging non-small cell lung cancerCancer Imaging, 2007
- Prospective Comparative Study of Integrated Positron Emission Tomography-Computed Tomography Scan Compared With Remediastinoscopy in the Assessment of Residual Mediastinal Lymph Node Disease After Induction Chemotherapy for Mediastinoscopy-Proven Stage IIIA-N2 Non–Small-Cell Lung Cancer: A Leuven Lung Cancer Group StudyJournal of Clinical Oncology, 2006